ANAB vs ADRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ANAB · AnaptysBio$46.63 ▼ 1.62%
ADRX · Adarx Pharmaceuticals$12.79 ▼ 9.68%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ANAB -8.6%
- ADRX -33.9%
Head to head
| Metric | ANAB | ADRX |
|---|---|---|
| Price | $46.63 | $12.79 |
| Change today | ▼ 1.62% | ▼ 9.68% |
| Market cap | $1.39B | $1.42B |
| Return, 3 months | -20.2% | – |
| Return, year to date | +44.3% | – |
| Return, 1 year | +76.6% | – |
| P/E (TTM) | 9.0 | – |
| P/B | 66.6 | 2.5 |
| P/E percentile vs own 5y | 93rd | 85th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +18.5% | +258.7% |
| Net profit growth (YoY) | +107.3% | -42.4% |
| Gross margin | – | – |
| Operating margin | 65.7% | -1,735.0% |
| Net margin | 12.8% | -1,434.1% |
| Return on equity | – | – |
| Analyst target vs. price | +71.6% | +173.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 45 | 35 |
| 30-day volatility | 47.9% | 78.8% |
| Max drawdown, 1 year | -34.9% | -38.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ADRX is the largest of the group by market value.
- ADRX is growing revenue fastest.
- ANAB keeps the most profit per dollar of sales.
- ANAB has been the calmest stock over the last 30 days.